High plasma HIV load in the CRF01-AE outbreak among injecting drug users in Finland

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 4, 2005, Pages 276-283

  Kivelä, Pia S ^a   Krol, Anneke ^b   Salminen, Mika O ^c   Geskus, Ronald B ^b   Suni, Jukka I ^d   Anttila, Veli Jukka ^a   Liitsola, Kirsi ^c   Zetterberg, Veera ^c   Miedema, Frank ^e   Berkhout, Ben ^e   Coutinho, Roel A ^b   Ristola, Matti A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d HUCH Laboratorydiagnostics ^*  (Finland)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; CD4 ANTIGEN; COCAINE; DIAMORPHINE;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MARKER; DRUG USE; EPIDEMIC; FEMALE; FINLAND; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; SELF INJECTION; SEROCONVERSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; T LYMPHOCYTE; VIRUS DETECTION; VIRUS LOAD; VIRUS STRAIN;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE OUTBREAKS; FINLAND; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; NETHERLANDS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 20244375553     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410021054     Document Type: Article

References (33)

1. Liitsola K, Ristola M, Holmstrom P, Salminen M, Brummer-Korvenkontio H, Simola S, et al. An outbreak of the circulating recombinant form AECM240 HIV-1 in the Finnish injection drug user population. AIDS 2000;14: 2613-5.
2. Wasi C, Herring B, Raktham S, Vanichseni S, Mastro TD, Young NL, et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS 1995;9:843-9.
3. Bobkov A, Kazennova E, Selimova L, Ladnaya N, Kravchenko A, Foley B, et al. HIV type 1 gag D/env G recombinants in Russia. AIDS Res Hum Retroviruses 1998; 14:1597-9.
4. Liitsola K, Tashkinova I, Laukkanen T, Korovina G, Smolskaja T, Momot O, et al. HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. AIDS 1998;12:1907-19.
5. Kuiken CL, Goudsmit J. Silent mutation pattern in V3 sequences distinguishes virus according to risk group in Europe. AIDS Res Hum Retroviruses 1994;10:319-20.
6. Galai N, Kalinkovich A, Burstein R, Vlahov D, Bentwich Z. African HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel. Lancet 1997;349:180-1.
7. Del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, Desmond N, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998;12:1203-9.
8. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999;13: 901-7.
9. Laurent C, Bourgeois A, Faye MA, Mougnutou R, Seydi M, Gueye M, et al. No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in western and west-central Africa: a 4-y prospective multicentre study. J Infect Dis 2002;186:486-92.
10. Neilson JR, John GC, Carr JK, Lewis P, Kreiss JK, Jackson S, et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999;73:4393-403.
11. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002;185:1244-50.
12. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. |J Infect Dis 1999;179:68-73.
13. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, et al. Relationship between HIV-1 env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001;15:293-9.
14. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, et al. Viral load differences in early infection with 2 HIV-1 subtypes. AIDS 2001;15:683-91.
15. Rinke de Wit TF, Tsegaye A, Wolday D, Hailu B, Aklilu M, Sanders E, et al. Primary HIV-1 subtype C infection in Ethiopia. J Acquit Immune Defic Syndr 2002;30:463-70.
16. Op de Coul EL, Prins M, Cornelissen M, van der Schoot A, Boufassa F, Brettle RP, et al. European and Italian Seroconverter Studies. Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997. AIDS 2001;15: 257-66.
17. van den Hoek JA, Coutinho RA, van Haastrecht HJ, van Zadelhoff AW, Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988;2:55-60.
18. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
19. Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics 1999;55:625-9.
20. Krol A, Flynn C, Viahov D, Miedema F, Coutinho RA, van Ameijden EJ. New evidence to reconcile in vitro and epidemiological data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Drug Alcohol Depend 1999;54:145-54.
21. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-53.
22. Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002;29:275-83.
23. Sperling PS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996;335:1621-9.
24. Shaffer N, Roongpisuthipong A, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young NL, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 1999;179:590-9.
25. Liitsola K, Holm K, Bobkov A, Pokrovsky V, Smolskaya T, Leinikki P, et al. An AB recombinant and its parental HIV type 1 strains in the area of the former Soviet Union: low requirements for sequence identity in recombination. UN-AIDS Virus Isolation Network. AIDS Res Hum Retroviruses 2000;16:1047-53.
26. Zetterberg V, Ustina V, Liitsola K, Zilmer K, Kalikova N, Sevastianova K, et al. Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia. AIDS Res Hum Retroviruses 2004;20:1148-56.
27. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
28. Margolick JB, Farzadegan H, Hoover DR, Saah AJ. Relationship between infectious cell-associated human immunodeficiency virus type 1 load, T-lymphocyte subsets, and stage of infection in homosexual men. J Infect Dis 1996;173:468-71.
29. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicentre Haemophilia Cohort Study. JAMA 1996;276:105-10.
30. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viraemia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicentre AIDS Cohort Study. J Infect Dis 2000;181: 872-80.
31. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, Christopherson C, et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 1999;37:2557-63.
32. Parekh B, Phillips S, Granade TC, Baggs J, Hu DJ, Respess R. Impact of HIV type 1 subtype variation on viral RNA quantitation. AIDS Res Hum Retroviruses 1999;15:133-42.
33. Vandamme AM, Schmit JC, van Dooren S, van Laethem K, Gobbers E, Kok W, et al. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:127-39.